WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2025)
Top general drug manufacturer stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...
OverviewZen RatingPriceValueGrowthFinancialsMomentumSentimentForecast
DividendsDue Diligence
A
General Drug Manufacturers is Zen Rated A and is the ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Market Cap
Price
Price Target
Upside/Downside
Top Analysts Upside/Downside
Consensus
Top Analysts Consensus
Analysts
Top Analysts
Fore. Revenue Growth
Fore. Earnings Growth
Forecast ROE
Forecast ROA
MIRA
MIRA PHARMACEUTICALS INC
$19.54M$1.18$17.001,340.68%Strong Buy1N/AN/A-250.24%-209.60%
LLY
ELI LILLY & CO
$771.32B$813.48$1.03k27.03%Strong Buy923.83%49.81%311.17%56.10%
SCLX
SCILEX HOLDING CO
$72.51M$0.30$14.334,709.73%Strong Buy373.14%N/AN/A-152.63%
ABBV
ABBVIE INC
$373.85B$211.77$215.241.64%Strong Buy176.87%86.32%889.28%21.88%
MRK
MERCK & CO INC
$238.89B$94.57$117.9224.69%Buy134.96%17.55%62.75%24.82%
GILD
GILEAD SCIENCES INC
$138.78B$111.44$108.95-2.23%Buy212.90%185.87%60.75%19.91%
OGN
ORGANON & CO
$3.95B$15.31$20.0030.63%Buy2-0.90%4.65%N/AN/A
JNJ
JOHNSON & JOHNSON
$391.98B$162.81$172.335.85%Buy122.78%25.91%41.32%16.40%
BIIB
BIOGEN INC
$20.41B$139.44$208.5549.56%Buy22-1.02%14.43%15.97%9.51%
PFE
PFIZER INC
$145.76B$25.72$31.5022.47%Buy8-1.07%28.12%17.73%7.33%
AMGN
AMGEN INC
$168.53B$313.71$324.923.57%Buy132.83%42.82%204.87%13.11%
BMY
BRISTOL MYERS SQUIBB CO
$119.75B$59.01$59.080.12%Hold12-4.29%N/A72.60%12.81%
NVS
NOVARTIS AG
$215.40B$109.06$120.0010.03%Hold12.12%16.00%43.77%18.85%
AMRN
AMARIN CORP PLC
$171.47M$0.41N/AN/AN/AN/A-5.00%N/AN/AN/A
SNY
SANOFI
$145.89B$57.75N/AN/AN/AN/A6.58%29.35%9.21%5.37%
AZN
ASTRAZENECA PLC
$240.64B$77.60N/AN/AN/AN/A5.67%33.41%22.32%8.75%
GSK
GSK PLC
$80.58B$39.49N/AN/AN/AN/A3.96%46.71%124.75%28.68%
GRFS
GRIFOLS SA
$5.49B$7.98N/AN/AN/AN/A14.28%889.69%14.59%3.97%
1

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Mar 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Gilead Sciences (NASDAQ:GILD)


Gilead Sciences (NASDAQ:GILD) is the #1 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Gilead Sciences (NASDAQ:GILD) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Gilead Sciences (NASDAQ:GILD) has a Due Diligence Score of 37, which is -3 points lower than the general drug manufacturer industry average of 40. Although this number is below the industry average, our proven quant model rates GILD as a "A".

GILD passed 13 out of 38 due diligence checks and has average fundamentals. Gilead Sciences has seen its stock return 50.17% over the past year, overperforming other general drug manufacturer stocks by 46 percentage points.

Gilead Sciences has an average 1 year price target of $108.95, a downside of -2.23% from Gilead Sciences's current stock price of $111.44.

Gilead Sciences stock has a consensus Buy recommendation according to Wall Street analysts. Of the 21 analysts covering Gilead Sciences, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) is the #2 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Pfizer (NYSE:PFE) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: B.

Pfizer (NYSE:PFE) has a Due Diligence Score of 54, which is 14 points higher than the general drug manufacturer industry average of 40.

PFE passed 18 out of 38 due diligence checks and has strong fundamentals. Pfizer has seen its stock lose -8.57% over the past year, underperforming other general drug manufacturer stocks by -13 percentage points.

Pfizer has an average 1 year price target of $31.50, an upside of 22.47% from Pfizer's current stock price of $25.72.

Pfizer stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Pfizer, 37.5% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 12.5% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Novartis Ag (NYSE:NVS)


Novartis Ag (NYSE:NVS) is the #3 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Novartis Ag (NYSE:NVS) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: B.

Novartis Ag (NYSE:NVS) has a Due Diligence Score of 40, which is equal to the general drug manufacturer industry average of 40.

NVS passed 15 out of 38 due diligence checks and has average fundamentals. Novartis Ag has seen its stock return 11.14% over the past year, overperforming other general drug manufacturer stocks by 7 percentage points.

Novartis Ag has an average 1 year price target of $120.00, an upside of 10.03% from Novartis Ag's current stock price of $109.06.

Novartis Ag stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Novartis Ag, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 11 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Novartis Ag (NYSE:NVS)


Novartis Ag (NYSE:NVS) has an annual dividend yield of N/A, which is N/A percentage points lower than the general drug manufacturer industry average of 2.68%. Novartis Ag's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Novartis Ag's dividend has shown consistent growth over the last 10 years.

Novartis Ag's dividend payout ratio of 63.8% indicates that its dividend yield is sustainable for the long-term.

2. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) has an annual dividend yield of 4.9%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.68%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 88.7% indicates that its high dividend yield is sustainable for the long-term.

3. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) has an annual dividend yield of 3.93%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.68%. Gsk's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 71.9% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 0.5% in the last day, and down -4.38% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Biogen (NASDAQ:BIIB)


Biogen (NASDAQ:BIIB) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 44 points higher than the general drug manufacturer industry average of 42. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -36.51% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -41 percentage points.

2. Organon & Co (NYSE:OGN)


Organon & Co (NYSE:OGN) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 43, which is 1 points higher than the general drug manufacturer industry average of 42. It passed 3 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -16.61% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -21 percentage points.

3. Gilead Sciences (NASDAQ:GILD)


Gilead Sciences (NASDAQ:GILD) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Gilead Sciences has a valuation score of 29, which is -13 points higher than the general drug manufacturer industry average of 42. It passed 2 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates GILD a Valuation Rating of "B".

Gilead Sciences's stock has gained 50.17% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 46 percentage points.

Are general drug manufacturer stocks a good buy now?

53.85% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 18.73% over the next year.

18.75% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 56.25% of general drug manufacturer stocks are rated B (Buy), 18.75% are rated C (Hold), 6.25% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 54.82x.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.